Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma C Wall

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|June 6, 2021
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccinationEmma C Wall, Mary Wu, Ruth Harvey, et al.
Lancet (London, England)|August 15, 2021
Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patientsEdward J Carr, Mary Wu, Ruth Harvey, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2023
Within-host SARS-CoV-2 viral kinetics informed by complex life course exposures reveals different intrinsic properties of Omicron and Delta variantsTimothy W Russell, Hermaleigh Townsley, Sam Abbott, et al.
Lancet (London, England)|January 22, 2022
Three-dose vaccination elicits neutralising antibodies against omicronMary Wu, Emma C Wall, Edward J Carr, et al.
ACS Central Science|March 27, 2023
O-Linked Sialoglycans Modulate the Proteolysis of SARS-CoV-2 Spike and Likely Contribute to the Mutational Trajectory in Variants of ConcernEdgar Gonzalez-Rodriguez, Mia Zol-Hanlon, Ganka Bineva-Todd, et al.
Ebiomedicine|June 11, 2026
Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergenceRuth Harvey, Ceilidh Welsh, Alexander Mp Byrne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2023
Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike ProteinVinit Upasani, Katie Townsend, Mary Y Wu, et al.
The Lancet. Infectious Diseases|June 8, 2023
Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infectionEdward J Carr, Mary Y Wu, Joshua Gahir, et al.
The Journal of Infection|August 23, 2025
Third exposure to COVID-19 infection or vaccination differentially impacts T cell responsesGift Ahimbisibwe, David Greenwood, Katalin Andrea Wilkinson, et al.
Plos One|March 21, 2024
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination historyHermaleigh Townsley, Joshua Gahir, Timothy W Russell, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|June 6, 2021
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccinationEmma C Wall, Mary Wu, Ruth Harvey, et al.
Lancet (London, England)|August 15, 2021
Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patientsEdward J Carr, Mary Wu, Ruth Harvey, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2023
Within-host SARS-CoV-2 viral kinetics informed by complex life course exposures reveals different intrinsic properties of Omicron and Delta variantsTimothy W Russell, Hermaleigh Townsley, Sam Abbott, et al.
Lancet (London, England)|January 22, 2022
Three-dose vaccination elicits neutralising antibodies against omicronMary Wu, Emma C Wall, Edward J Carr, et al.
ACS Central Science|March 27, 2023
O-Linked Sialoglycans Modulate the Proteolysis of SARS-CoV-2 Spike and Likely Contribute to the Mutational Trajectory in Variants of ConcernEdgar Gonzalez-Rodriguez, Mia Zol-Hanlon, Ganka Bineva-Todd, et al.
Ebiomedicine|June 11, 2026
Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergenceRuth Harvey, Ceilidh Welsh, Alexander Mp Byrne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2023
Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike ProteinVinit Upasani, Katie Townsend, Mary Y Wu, et al.
The Lancet. Infectious Diseases|June 8, 2023
Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infectionEdward J Carr, Mary Y Wu, Joshua Gahir, et al.
The Journal of Infection|August 23, 2025
Third exposure to COVID-19 infection or vaccination differentially impacts T cell responsesGift Ahimbisibwe, David Greenwood, Katalin Andrea Wilkinson, et al.
Plos One|March 21, 2024
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination historyHermaleigh Townsley, Joshua Gahir, Timothy W Russell, et al.
Pageof 5